Germany · Delayed Price · Currency is EUR Terns Pharmaceuticals Company Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity.
The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.
It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
The company was incorporated in 2016 and is headquartered in Foster City, California.
| Country | United States |
| Founded | 2016 |
| Industry | Pharmaceutical Preparations |
| Employees | 59 |
| CEO | Amy Burroughs |
Contact Details
Address: 1065 East Hillsdale Boulevard Foster City, California 94404 United States | |
| Phone | 650 525 5535 |
| Website | ternspharma.com |
Stock Details
| Ticker Symbol | 430 |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Amy Burroughs | Chief Executive Officer |
| Andrew Gengos | Chief Financial Officer |